TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today opinion by Steven Grossman and Michael Miller argues that a more pro-vaccine Congress after the 2026 midterms may still have limited power to block executive and state-level policy changes. The authors expect renewed federal action after the election, but those forecasts are analysis, not confirmed future events.
A MedPage Today opinion published October 20 argues that a more pro-vaccine Congress after the November 2026 midterms may not be enough to protect vaccine policy from federal and state challenges. Authors Steven Grossman, JD, and Michael Miller, MD, say executive actions and legislative efforts at the state level could continue even if vaccine supporters gain seats, though the election outcome and future policies remain unsettled.
Grossman and Miller write that, based on mid-October polling, public health advocates could have more allies when the new Congress convenes on January 3, 2027. They describe a Democratic House as near certain and a Democratic Senate as a 50-50 possibility, but these are the authors’ assessments of polls, not election results. They argue that congressional support would help but would not, on its own, shield vaccine policy from administrative or state-level action.
The authors point to advocacy activity during 2026, including coordinated opposition to federal and state initiatives. They cite a lawsuit challenging changes to the Advisory Committee on Immunization Practices (ACIP) and associated reductions in routine vaccine recommendations. They also describe responses to changes affecting HHS and FDA advisory groups, respiratory vaccine guidance and state efforts to broaden school vaccine exemptions. The piece says many medical societies issued their own routine-vaccine recommendations that largely matched pre-2025 ACIP guidance.
Grossman and Miller also say vaccine policy did not become a larger national election issue than advocates had hoped. They cite attention to two wars and higher energy and food prices, a mild 2025-26 flu season, measles outbreaks and deaths, and divisions within the Make America Healthy Again movement. Their account and conclusions are those of the authors; the piece does not provide a full accounting of campaign effects or independently establish that any one factor determined voters’ priorities.
Congressional Support Has Limits
The argument matters because federal vaccine policy is shaped by more than Congress. The authors warn that executive agencies can change recommendations and priorities, while state lawmakers can alter school exemption rules. Congress may conduct oversight or pass legislation, but the opinion contends that those tools may not quickly reverse every administrative change, particularly if implementation and court disputes continue.
For families, clinicians and public health agencies, changes to recommendations or school requirements can affect which vaccines are advised and how communities respond. The authors’ forecast is not proof that further restrictions will occur. It does, however, highlight why election results alone may not settle disputes over vaccine policy: the rules, legal authority and enforcement decisions remain contested across several levels of government.
Advocacy and Policy Disputes in 2026
The opinion places the election debate against actions it says expanded during 2025 under President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr. In 2026, the authors describe advocacy groups organizing against changes to vaccine advisory bodies and guidance. Separately, they say Kennedy temporarily pursued less direct policies after controversies over ACIP, while maintaining his broader views. These characterizations and explanations are presented by the authors.
Grossman and Miller say medical organizations published guidance resembling the former ACIP recommendations, while advocacy coalitions coordinated responses to federal and state developments. They also describe an effort to make vaccine policy a more visible campaign issue. The piece’s central conclusion is that such organizing has raised awareness but has not removed the policy risks the authors see continuing beyond the midterms.
““Heavy lifting from pro-vaccine policymakers and advocates will be essential over the next 2 years, but this need will likely stretch into 2029 and beyond.””
— Steven Grossman, JD, and Michael Miller, MD, in their MedPage Today opinion
Election Results and Actions Remain Open
The midterms had not produced results in the source material, and polling does not establish which party will control either chamber. The authors’ expectations about a Democratic House and the Senate’s likelihood are predictions. It is also unclear which vaccine-related proposals, if any, the administration or state governments will pursue after the election.
The opinion anticipates that legal and political conflicts could involve executive authority, congressional oversight and court rulings. The source does not identify a specific post-election policy timetable or detail the likely outcome of the cited lawsuit. Its claims about the administration’s approach to courts and executive power are the authors’ analysis, not a ruling about the legality of any future action.
The New Congress Takes Office
The new Congress is scheduled to convene on January 3, 2027, after voters decide control of the House and Senate. Attention will then turn to the administration’s agency decisions, congressional oversight and any new state-level measures affecting vaccine recommendations or school requirements. The authors say advocates should prepare for continued activity, but the source does not name a confirmed next federal proposal.
Further developments to watch include the progress of the ACIP-related lawsuit, any changes to federal advisory groups or vaccine guidance, and state legislation on exemptions. Until those decisions occur, the authors’ post-election scenario remains a warning and forecast rather than a settled account of what will happen.
Key Questions
What is the central argument of the opinion?
Grossman and Miller argue that even if vaccine supporters gain seats in Congress, federal executive actions and state policies could continue to affect vaccine recommendations and access.
Have the 2026 midterm results been confirmed in the source?
No. The opinion relies on mid-October polling and offers projections about control of Congress. It does not report election results.
What 2026 policy disputes do the authors cite?
They cite a lawsuit challenging changes to ACIP and reductions in routine vaccine recommendations, changes to HHS and FDA advisory groups, updates to respiratory vaccine guidance, and state efforts to expand school vaccine exemptions.
Is the predicted post-election federal action confirmed?
No. The authors forecast that Kennedy may pursue new or previously blocked policies after the midterms. The source does not report that those future actions have been announced or adopted.
What is the next scheduled political milestone?
The new Congress is scheduled to convene on January 3, 2027. Election results and subsequent agency, court and state actions will clarify how vaccine policy develops.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
